Analysis: Drugmakers face more scrutiny of discordant U.S. prices

[riky]

Analysis: Drugmakers face more scrutiny of discordant U.S. prices

By Deena Beasley LOS ANGELES (Reuters) - The world's biggest drug makers have for years enjoyed rich premiums for their medicines in the U.S. market. Those days may be coming to an end. Companies like Pfizer Inc and AstraZeneca have grown dependent on higher U.S. prices to generate profits as generic rivals to their best-selling medicines enter the world market, Europe's government-run health plans clamp down on spending and sales growth in emerging markets stutters. ...

Source: You are not allowed to view links. Register or Login